Efficacy of Vonoprazan based dual therapy with amoxicillin versus standard triple therapy for Helicobacter pylori eradication in Thailand

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210216003

Enrollment

128

Registered

2021-02-16

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy of the 7-day vonoprazan and amoxicillin dual therapy for H. pylori treatment and compared it with standard triple therapy Helicobacter pylori vonoprazan

Interventions

7 days vonoprazan 20 mg bid + amoxicillin 1,000 mg,14 days omeprazole 20 mg bid + amoxicillin 1,000 mg and clarithromycin 500 mg

Active Comparator Drug,No Intervention Drug

VA-dual,OAC-triple

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) subjects undergoing gastrointestinal endoscopy at Department of Gastroenterology Phramongkutklao Hospital during 1 August 2019 to 28 February 2020 2) aged 18 years or over 3) diagnosis of H.pylori infection using upper GI endoscopy with the rapid urease test and positive test result of the infection.

Exclusion criteria

Exclusion criteria: 1) GFR <30 ml/min/1.73m2 2) history of drug resistance used in research studies 3) pregnant women or breastfeeding mothers 4) History treatment of H.pylori infection 5) Subjects in critical condition 6) Subjects to be diagnosed with neuroendocrine tumor, HIV infection

Design outcomes

Primary

Measure	Time frame
Eradication rate 6 wks Remission rate after treatment	—

Secondary

Measure	Time frame
Side effect 6 wks Questionare	—

Countries

Thailand

Contacts

Public ContactVeerayut Anansawat

Phramongkutklao college of medicine

drveerayut@gmail.com0922627060

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026